Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Mallinckrodt
Cipla
Baxter
Dow
Boehringer Ingelheim
Cantor Fitzgerald
Merck

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020641

« Back to Dashboard

NDA 020641 describes CLARITIN HIVES RELIEF, which is a drug marketed by Bayer Healthcare Llc and is included in three NDAs. It is available from five suppliers. Additional details are available on the CLARITIN HIVES RELIEF profile page.

The generic ingredient in CLARITIN HIVES RELIEF is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and forty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.
Summary for 020641
Tradename:CLARITIN HIVES RELIEF
Applicant:Bayer Healthcare Llc
Ingredient:loratadine
Patents:1
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 020641
Suppliers and Packaging for NDA: 020641
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLARITIN loratadine SYRUP;ORAL 020641 NDA Bayer HealthCare LLC. 11523-4360 11523-4360-1 1 BOTTLE in 1 CARTON (11523-4360-1) > 60 mL in 1 BOTTLE
CLARITIN loratadine SYRUP;ORAL 020641 NDA Bayer HealthCare LLC. 11523-4360 11523-4360-2 1 BOTTLE in 1 CARTON (11523-4360-2) > 120 mL in 1 BOTTLE

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:SYRUP;ORALStrength1MG/ML
Approval Date:Nov 27, 2002TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 1, 2018Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:SYRUP;ORALStrength1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 19, 2003TE:RLD:Yes

Expired US Patents for NDA 020641

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Deloitte
Cipla
Cantor Fitzgerald
McKinsey
Merck
Fish and Richardson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.